RHP 5.54MTRN 4.28PSMT 0ESLOY 0MSFT -8.48META -4.53HLPR.TO 0VDY.TO -0.65
Pfizer Inc (PFE)
The ultimate 360° Tracker Your financial life in one place, automatically

NYSE:PFE

Pfizer Inc (PFE)

24.04
-0.68 (2.75%)
as of Jun 24, 2026, 8:00:00 pm Market Open.
581 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconJun 24, 2026, 12:00 am

This summary was created by AI, based on 29 opinions in the last 12 months.

Pfizer Inc (PFE) is facing significant challenges including a patent cliff and the aftermath of over-earning during the COVID-19 pandemic. The company has made efforts to bolster its drug pipeline through acquisitions, such as Seagen, but many experts express concerns about the lack of earnings momentum and blockbusters to drive growth. While the stock offers an attractive dividend yield (around 6-7%), there is a prevailing sentiment around its long-term growth prospects as reliance on cost-cutting and strategic acquisitions seems insufficient. Analysts highlight the need for a new growth catalyst, particularly in oncology, to reassure investors as the dividend yield may be at risk if substantial progress with new drugs is not achieved. Overall, patience is emphasized by many experts, with a hope that the stock will eventually perform better amid potential improvements in government policies and market conditions.

consensus icon
Consensus
Hold
valuation icon
Valuation
Undervalued
review icon
Similar
AstraZeneca, AZN
TOP PICK

Pfizer Inc(PFE)

Mar 29, 2004
Has reached about a 20-year valuation low. Relatively cheap.
Photo of Ross HealyRoss Healy
Owned
Unlock Rating
$35.02

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Mar 29, 2004
Have a great lineup of existing drug products and lots more in the pipeline. At about 18 X earnings. Cheap.
Photo of Rob CallanderRob Callander
Owned
Unlock Rating
$35.02

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Mar 19, 2004
Thinks it's going to grow earnings at 15% this year.
Photo of Paul O'NeilPaul O'Neil
Owned
Unlock Rating
$33.95

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Mar 09, 2004
(A top pick Dec 29/03. Up 7.2%.) Still likes. As far and away the best growth profile in pharmaceuticals. Growing the fastest even though it's the most expensive.
Photo of John Sinkins, CFAJohn Sinkins, CFA
Owned
Unlock Rating
$37.30

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Feb 19, 2004
Have a very good pipeline. Faces significant generic exposure for the next few years because of patent exposure. On his focus list and will probably stay there for some time.
Photo of Matt BaraschMatt Barasch
No
Unlock Rating
$37.28

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Feb 17, 2004
Feels it is going to move substantially higher in the next 12/18 months.
Photo of Gavin GrahamGavin Graham
Owned
Unlock Rating
$37.75

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
WAIT

Pfizer Inc(PFE)

Feb 10, 2004
Had a good run. Benefit you to wait. Buy when it is down a few dollars from current price.
Photo of Brad WillockBrad WillockUnlock Rating
$38.00

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Jan 15, 2004
A great pharmaceutical company. Has a huge stable of drugs coming through.
Photo of Bob StodgellBob Stodgell
Owned
Unlock Rating
$34.82

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Jan 07, 2004
(A past top pick Dec 6/03. Up 6.7%.) Still likes it. A tremendous pipeline. Not facing a lot of patent issues. Very reasonable valuation. Will be a solid 15/20% grower.
Photo of Laura WallaceLaura Wallace
Owned
Unlock Rating
$36.79

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Dec 29, 2003
Pharmaceutical companies have been laggards. Should have revenue growth of about 40% and earnings at about 20% in 2004. 2 1/2% dividend.
Photo of John Sinkins, CFAJohn Sinkins, CFA
Owned
Unlock Rating
$35.00

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Pfizer Inc(PFE)

Dec 12, 2003
One of the best pharmaceutical companies. The large pharmaceutical companies are increasingly facing more and more headwinds. If it reaches the upper $30's, consider selling.
Photo of Jonathen Wellum, B. Comm, B. ScJonathen Wellum, B. Comm, B. Sc
Owned
Unlock Rating
$34.40

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Dec 01, 2003
Trading at 15X 2004 earnings. Will have a growth rate of 15/20%. Well diversified number of drugs. Nothing coming off patent until 2007. The whole area has been hit hired on the concerns of US pricing of drugs, but feels the bill will be positive.
Photo of Laura WallaceLaura Wallace
Owned
Unlock Rating
$34.17

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Nov 28, 2003
(A top pick July 10/03. No change.) There is something wrong with the drug stocks. They are all trading poorly and he thinks they want to go lower.
Photo of Ross HealyRoss HealyUnlock Rating
$33.57

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Nov 19, 2003
Will have 100 different drugs in the next 3 or 4 years. Have enormous cash flow. Paying down their debt. Debt/equity ratio is quite strong. Weak US$ will be of benefit as they are international. 2% dividend.
Photo of Bob StodgellBob Stodgell
Owned
Unlock Rating
$34.18

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Oct 27, 2003
Pharmaceutical sector has been very frustrating. OK buy for a long-term investment. Could still be some downside. Expecting to file 22 to 25 new drugs between now and 2006. Generates tremendous cash flow. Earnings visibility is good.
Photo of Stephane RochonStephane RochonUnlock Rating
$30.97

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
Showing 736 to 750 of 883 entries

You may also like

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

MSFT -8.48$365.46
PPL.TO -0.83$66.15
CVE.TO -1.49$35.09
TOU.TO -0.68$59.86
GOOG -1.04$345.04

Today's Top Picks

RHP 5.54$129.77
MTRN 4.28$269.62
PSMT 0$
ESLOY 0$95.66
MSFT -8.48$365.46

Popular Articles

Latest Sell Signals

ATD.TO 1.89$93.76
ITB 5.99$103.32
GLD -11.4$365.92
MU -3.26$1048.51
MU -3.26$1048.51

Most Recent Experts

Brendan Caldwell

Brendan Caldwell

Caldwell Securities

Liz Young, Head of investment strategy at SoFi

Liz Young, Head of investment strategy at SoFi

SoFi

Stephen Weiss, Founder, Short Hills Capital Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Joe Terranova

Joe Terranova

Virtus Investment Partners

Paul Harris, CFA

Paul Harris, CFA

Harris Douglas Asset Management

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica